Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
January 26, 2026World Journal of Surgery

A New N2 Descriptor for Resectable Non‐Small Cell Lung Cancer: The Classification Based on Skip Metastasis and the Number of N2 Station Involvement

View Full Paper
Ask AI
Bookmark
Share

Authors

XHXiao HuangFXFengkai XuCTCheng Tao

Discussion

Loading...

Member takes

Overview

Retrospective review assesses prognostic value of new N2 descriptor in NSCLC, suggesting better survival prediction.

Key Points

  • This research aims to evaluate the clinical significance and prognostic value of a new N2 descriptor for NSCLC.
  • Conducted a retrospective review of 533 patients with stage pN2 NSCLC.
  • Classified patients into three groups: skip N2a, skip N2b/nonskip N2a, and nonskip N2b.
  • Analyzed clinic characteristics, survival outcomes, and metastasis patterns among groups.
  • Significant prognostic differences found between the three N2 groups for both overall survival (OS) and disease-free survival (DFS).
  • Better prognostic value for the new N2 descriptor compared to the ninth edition N2 classification.
  • Skip patients demonstrated improved survival outcomes and distinct lymph node metastasis patterns.

Cite This Study

Huang et al. (2026) studied this question.

synapsesocial.com/papers/69770413722626c4468e91f3https://doi.org/10.1002/wjs.70241
View Full Paper
Ask AI
Bookmark
Share